Novo Nordisk A/S
看多

NVO - buying quality compounder during panic

185
Financials great, P/E 20 is very reasonable. Top line 20%+, LLY competition threats seems exaggerated. Last time was this oversold in 2017 and quickly rebounded. Impossible to replicate knowledge and ability to innovate. Started entry position at 78.5, will be DCA until it finds the bottom (if not already)

Happy weekend

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。